Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Adaptive Transfer of B10 Cells: a Novel Therapy for Chronic Rejection after Solid Organ Transplantation.

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Strategies to Achieve Immune Tolerance in Allogeneic Solid Organ Transplantation.

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

Advances in T follicular helper and T follicular regulatory cells in transplantation immunity

Advances in Transplantation Tolerance

Activation and regulation of alloreactive T cell immunity in solid organ transplantation

B Cell–mediated Immune Regulation and the Quest for Transplantation Tolerance

IMMUNE MODULATION AND PREVENTION OF ALLOGENEIC GRAFT REJECTION BY THERAPEUTIC DENDRITIC CELLS:

An Unexpected Counter‐Regulatory Role of IL‐10 in B‐Lymphocyte‐Mediated Transplantation Tolerance

Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation

Transplantation tolerance: don't forget about the B cells

SYNERGISTIC TOLERANCE BY ADOPTIVE TRANSFER OF TOLEROGENIC DENDRITIC CELLS AND T REGULATORY CELLS:

The Role Of Selective Depletion Of Alloreactive Donor T Cells In Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation.

An Immunotherapeutic Strategy for Prolonging Graft Survival in Mice.

B cells with regulatory properties in transplantation tolerance